Story
BlossomHill Therapeutics Shares Dip in U.S. Market Debut

BlossomHill Therapeutics (BLSM), a biopharmaceutical firm focused on oncology, saw its shares decline in early trading on Friday after making its public debut on the U.S. stock market. The stock fell more than 1% to $15.80 per share shortly after the market opened, according to a report from Zhitong Finance.
Company Profile and Pipeline
Founded in 2020 and headquartered in San Diego, California, BlossomHill Therapeutics specializes in the development of small-molecule drugs for cancer. The company's strategy involves identifying structural weaknesses in existing treatments and engineering new compounds designed to overcome them.
Its lead drug candidate, known as BH-30643, targets a form of non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR). This candidate is currently undergoing a global Phase 1/2 clinical trial.
AdRegulatory Outlook
BlossomHill has outlined a clear timeline for its development program. The company stated its intention to hold an end-of-Phase-1 meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026.
Discussions with the FDA are expected to focus on the recommended dosing for the Phase 2 trial and to explore a potential accelerated approval pathway for BH-30643 in certain patient populations. Such a pathway could significantly shorten the time to market if the clinical data is sufficiently strong.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.